BAL PHARMA LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 119.2 INR | +0.21% |
|
+4.10% | +18.66% |
| May. 28 | Bal Pharma Limited Recommends Dividend | CI |
| May. 28 | Bal Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 2.81B 33.68M | Sales 2023 | 3.04B 36.44M | Capitalization | 1.05B 12.58M |
|---|---|---|---|---|---|
| Net income 2022 | 56M 671K | Net income 2023 | 25M 299K | EV / Sales 2022 | 0.93 x |
| Net Debt 2022 | 1.01B 12.07M | Net Debt 2023 | 1.26B 15.05M | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
29.1
x | P/E ratio 2023 |
40.8
x | Employees | 869 |
| Yield 2022 |
0.93% | Yield 2023 |
1.49% | Free-Float | 33.71% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | +0.21% | ||
| 1 week | +4.10% | ||
| Current month | +4.04% | ||
| 1 month | +19.35% | ||
| 3 months | +23.83% | ||
| 6 months | +9.25% | ||
| Current year | +18.66% |
1 week
116.25
125.00
1 month
97.00131.94
Current year
89.20132.20
1 year
80.60132.20
3 years
63.40148.50
5 years
24.10148.50
10 years
24.10167.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 94-07-31 | |
| Director of Finance/CFO | - | 23-06-01 | |
Abdul Basith
CMP | Compliance Officer | - | 23-07-16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 94-07-31 | |
C. V. Srinivas
BRD | Director/Board Member | 58 | 19-06-28 |
| Director/Board Member | - | 19-09-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 119.2 | +0.21% | 6 246 |
| 24-06-13 | 119 | -1.29% | 3,240 |
| 24-06-12 | 120.6 | -0.17% | 5,342 |
| 24-06-11 | 120.8 | +1.17% | 7,144 |
| 24-06-10 | 119.4 | +4.19% | 9,662 |
Delayed Quote Bombay S.E., June 14, 2024 at 03:53 am EDT
More quotes
Bal Pharma Limited is a pharmaceutical company, which is engaged in manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers range of APIs includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers range of formulations products covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +18.66% | 22.35M | |
| +51.54% | 795B | |
| -7.20% | 350B | |
| +18.67% | 328B | |
| +7.48% | 294B | |
| +17.47% | 245B | |
| +0.86% | 222B | |
| +11.05% | 215B | |
| +3.64% | 160B | |
| -3.96% | 157B |
- Stock Market
- Equities
- BALPHARMA Stock
